+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol

Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol

Forensic Science International 265: 153-159

Tramadol concentrations and analgesic effect are dependent on the CYP2D6 enzymatic activity. It is well known that some genetic polymorphisms are responsible for the variability in the expression of this enzyme and in the individual drug response. The detection of allelic variants described as non-functional can be useful to explain some circumstances of death in the study of post-mortem cases with tramadol. A Sanger sequencing methodology was developed for the detection of genetic variants that cause absent or reduced CYP2D6 activity, such as *3, *4, *6, *8, *10 and *12 alleles. This methodology, as well as the GC/MS method for the detection and quantification of tramadol and its main metabolites in blood samples was fully validated in accordance with international guidelines. Both methodologies were successfully applied to 100 post-mortem blood samples and the relation between toxicological and genetic results evaluated. Tramadol metabolism, expressed as its metabolites concentration ratio (N-desmethyltramadol/O-desmethyltramadol), has been shown to be correlated with the poor-metabolizer phenotype based on genetic characterization. It was also demonstrated the importance of enzyme inhibitors identification in toxicological analysis. According to our knowledge, this is the first study where a CYP2D6 sequencing methodology is validated and applied to post-mortem samples, in Portugal. The developed methodology allows the data collection of post-mortem cases, which is of primordial importance to enhance the application of these genetic tools to forensic toxicology and pathology.

(PDF emailed within 0-6 h: $19.90)

Accession: 058830365

Download citation: RISBibTeXText

PMID: 26926096

DOI: 10.1016/j.forsciint.2016.02.004

Related references

Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. European Journal of Clinical Pharmacology 62(7): 513-521, 2006

Modelling the pharmacokinetics of tramadol: on the difference between CYP2D6 extensive and poor metabolizers. Journal of Theoretical Biology 254(3): 568-574, 2008

Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Science International 135(1): 9-15, 2003

Trends in the detection of drugs of abuse in post-mortem blood samples. Clinical Chemistry 47(S6): A74-A75, June, 2001

Mutant alleles of CYP2D6 in 36 poor metabolizers of debrisoquine. European Journal of Clinical Pharmacology 52(SUPPL ): A78, 1997

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics Journal 7(6): 408-410, 2007

The detection of iidelta 9 tetra hydro cannabinol in post mortem blood samples. Journal of Analytical Toxicology 3(4): 129-132, 1979

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. British Journal of Clinical Pharmacology 75(2): 538-549, 2013

CYP2D6 poor metabolizers in depressed women of Mexican origin. Clinical Pharmacology & Therapeutics 75(2): P41, February, 2004

Pharmacokinetics of buflomedil in poor and extensive CYP2D6 and CYP2C19 metabolizers. Fundamental & Clinical Pharmacology 14(3): 238, May-June, 2000

Low doses of oral haloperidol do not cause QT prolongation in poor metabolizers of CYP2D6. Clinical Pharmacology & Therapeutics 71(2): P53, February, 2002

Chlorpheniramine plasma antagonist activity in poor and extensive metabolizers of CYP2D6. Clinical Pharmacology & Therapeutics 55(2): 170, 1994

Primers targeted to CYP2D6 gene for detecting poor metabolizers of drugs. Official Gazette of the United States Patent & Trademark Office Patents 1200(3): 2144, July 15, 1997

Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. Journal of Clinical Psychopharmacology 20(3): 347-349, 2000